Director, Clinical Development – Immunology

A great culture, grounded in our C.O.R.E. values:

C

aring,

O

riginal,

R

We are seeking an experienced non-MD Clinical Scientist for a Director, Clinical Development role to support the scientific planning and execution of one or more clinical trials in inflammation & immunology. This role involves co-leading studies with a medical director and working closely with cross-functional teams to design, implement, oversee and analyze clinical studies to advance the development of innovative dermatology and/or respiratory therapies. In this role you will contribute scientific expertise and strategic insights to ensure the successful progression of clinical programs.

Collaborate with cross-functional teams to develop clinical documents for trials with scientific rigor, such as protocol, investigator brochure, clinical study report, scientific publications/presentations, etc.

Contribute scientific input and implementation into the study design and execution, including but not limited to selection of appropriate endpoints, patient populations, and study methodologies; site selection; investigator meetings; and study initiation activities

Monitor the clinical trials for both quality and safety, ensuring adherence to protocols, timelines, and quality standards

Analyze clinical trial data, interpret results, and provide scientific insights to guide decision-making

Founded in 2022, Apogee Therapeutics, Inc. (Ticker: APGE) is a well-funded, Nasdaq listed company that offers the opportunity to work in a fast-paced, highly dynamic environment. At Apogee, you can actively contribute to shaping the company culture, take on various roles and responsibilities, and grow professionally.

Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart (APG777), the company’s most advanced program, is being initially developed for the treatment of atopic dermatitis (AD), which is the largest and one of the least penetrated I&I markets, as well as asthma. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of leadership and expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care.

We are a fast-paced company committed to building an exceptional culture, founded on our C.O.R.E. values:

C

aring,

O